FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a vaccine containing antigen Plasmodium. Substance of the invention involves a new application of vaccine RTS, S/AS02A, representing a P. Falciparum (CS) circumsporozoite protein matched with amino acids 207-395, protein CS, clone 3D7, strain NF54 P. Falciparum fused in a reading frame through a linear linker with HBSAg N-end and a hepatitis B cell surface antigen (HBSAg) in a combination with a pharmaceutically acceptable adjuvant containing 3D-MPL and QS21 for severe malaria vaccination of children aged under 5.
EFFECT: enlarging the field of use of the vaccine.
7 cl, 3 tbl, 3 dwg
